Licain

Lidocaine Hydrochloride, the active ingredient in Licain, is a local anesthetic presented as a sterile solution for epidural, intramuscular and intravenous use. It provides local anesthesia for surgical and diagnostic procedures and helps manage pain in adult patients.

GNH USA supplies Licain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Licain (lidocaine hydrochloride) is a local anesthetic used to block nerve conduction in various clinical settings.

- Surgical procedures: provides localized numbness to facilitate operative interventions. - Diagnostic procedures: enables painless performance of endoscopic or imaging studies. - Acute pain management: reduces postoperative or procedural pain in adult patients.

Adverse reactions may occur with the use of lidocaine hydrochloride.

Common Side Effects: - Burning or stinging at the injection site. - Tingling, numbness, or mild paresthesia. - Transient hypotension. - Headache. - Nausea. - Dizziness.

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia. - Seizures or central nervous system toxicity. - Severe allergic reactions such as anaphylaxis. - Methemoglobinemia. - Respiratory depression. - Persistent neurologic deficits.

When using Licain, clinicians should observe several safety measures.

- Allergy assessment: avoid in patients with known lidocaine hypersensitivity. - Cardiovascular monitoring: use caution in patients with heart block, arrhythmias, or severe cardiac disease. - Hepatic impairment: consider dose reduction as lidocaine is metabolized by the liver. - Concurrent CNS depressants: monitor for enhanced toxicity when combined with other central nervous system depressants. - Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. - Store below 25°C: keep in the original container, protect from moisture and light.

Lidocaine may interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may cause severe cardiotoxicity. - Beta‑blockers: increase risk of bradycardia and hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise systemic lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may increase bleeding tendency. - General anesthetics (e.g., propofol, volatile agents): additive central nervous system depression. - Loop diuretics (e.g., furosemide): may alter plasma protein binding and affect lidocaine levels.